Pharmacodynamics and Proteomic Analysis of Acalabrutinib Therapy: Similarity of On-Target Effects to Ibrutinib and Rationale for Combination Therapy

Acalabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously treated chronic lymphocytic leukemia (CLL), however, complete remissions were limited. To elucidate on-target and pharmacodynamic effects of acalab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Patel, Viral Kumar, Lamothe, Betty, Ayres, Mary L., Gay, Jason, Cheung, Jean, Balakrishnan, Kumudha, Ivan, Cristina, Morse, Joshua, Nelson, Mark, Keating, Michael J., Wierda, William G., Marszalek, Joseph R., Gandhi, Varsha
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871548/
https://ncbi.nlm.nih.gov/pubmed/29099493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados